Table 1.
|
Ec-ESBL (N=100) |
Ec-MRnoB (N=100) |
||||||
---|---|---|---|---|---|---|---|---|
Agent | Range | MIC50 | MIC90 | %R | Range | MIC50 | MIC90 | %R |
Amoxicillin |
64-≥256 |
≥256 |
≥256 |
100 |
2-≥256 |
≥256 |
≥256 |
99 |
Amoxicillin-Clavulanic acid |
8-16 |
4 |
8 |
41 |
8-≥128 |
8 |
32 |
83 |
Piperacillin |
32-≥64 |
≥64 |
≥64 |
100 |
≤16-≥64 |
≥64 |
≥64 |
84 |
Piperacillin-Tazobactam |
≤0.5-≥256 |
4 |
16 |
16 |
≤0.25-≥256 |
2 |
4 |
6 |
Cefoxitina |
≤2-32 |
≤2 |
8 |
5 |
≤2-≥32 |
4 |
8 |
8 |
Cefotetana |
≤1-8 |
≤1 |
≤1 |
0 |
≤1-≥32 |
≤1 |
≤1 |
2 |
Cefotaxime |
32-≥128 |
≥128 |
≥128 |
100 |
≤0.5-128 |
≤0.5 |
≤0.5 |
5 |
Ceftazidime |
≤0.5-≥128 |
2 |
16 |
23 |
≤0.5-128 |
≤0.5 |
≤0.5 |
8 |
Cefepime |
≤1-≥32 |
≥32 |
≥32 |
96 |
≤1-4 |
≤1 |
<1 |
1 |
Aztreonam |
2-≥64 |
16 |
≥64 |
96 |
≤0.5-32 |
≤0.5 |
≤0.5 |
6 |
Imipenem |
≤0.5-1 |
≤0.5 |
≤0.5 |
0 |
≤0.5-2 |
≤0.5 |
≤0.5 |
0 |
Meropenem |
≤0.5 |
≤0.5 |
≤0.5 |
0 |
≤0.5 |
≤0.5 |
≤0.5 |
0 |
Gentamicin |
≤0.5-≥256 |
1 |
32 |
19 |
0.5-≥256 |
64 |
256 |
96 |
Tobramycin |
0.5-256 |
1 |
8 |
17 |
≤0.25-256 |
8 |
32 |
89 |
Amikacin |
≤0.5-8 |
2 |
4 |
0 |
1-8 |
2 |
4 |
0 |
Nalidixic acida |
1-≥256 |
≥256 |
≥256 |
89 |
1-≥256 |
≥256 |
≥256 |
98 |
Ciprofloxacina |
≤0.5-≥256 |
16 |
128 |
74 |
≤0.25-≥256 |
32 |
128 |
93 |
Tetracyclinea |
0.5-≥256 |
256 |
256 |
80 |
≤0.25-256 |
256 |
256 |
84 |
Doxycyclinea |
≤0.5-128 |
16 |
64 |
76 |
≤0.25-128 |
32 |
64 |
79 |
Tigecyclineb |
≤0.5-1 |
≤0.5 |
≤0.5 |
0 |
≤0.25-0.5 |
≤0.25 |
≤0.25 |
0 |
Trimethoprim-Sulfamethoxazole | ≤0.5-≥32 | ≥32/608 | ≥32/608 | 67 | ≤0.5-≥32 | ≥32/608 | ≥32/608 | 98 |
a CLSI 2011 breakpoints. b FDA breakpoints.